These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22020317)

  • 1. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
    Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
    Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
    Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
    Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
    Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
    Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
    Koizumi W; Akiya T; Sato A; Sakuyama T; Sasaki E; Tomidokoro T; Hamada T; Fujimori M; Kikuchi Y; Shimada K; Mine T; Yamaguchi K; Sasaki T; Kurihara M
    Cancer Chemother Pharmacol; 2010 May; 65(6):1093-9. PubMed ID: 19727730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
    van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
    J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer].
    Iwatani Y; Shimada Y; Ohshima T; Kusunoki N; Yamazaki T; Miyazaki N
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1129-32. PubMed ID: 11525030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.